ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/haematology/lymphoma/other-b-cell-lymphoma
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Lymphoma / Other B-cell lymphoma
51
trial(s) found.
NCT06943872
Haem
Phase 3
Recruiting
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
BGB-11417-303
)
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2217 - Kogarah - St George Hospital
2480 - Lismore - Lismore Base Hospital
2500 - Wollongong - Wollongong Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6005 - West Perth - Perth Blood Institute
6168 - Cooloongup - Rockingham Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06846671
Haem
Phase 3
Recruiting
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors (
CaDAnCe-302
)
BTK PROTAC degrader
Bcl2 inhibitor
PI3K delta inhibitor
alkylating agent
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4350 - Toowoomba - Toowoomba Hospital
WA
6005 - West Perth - Perth Blood Institute
NZ
NZ.0622 - Takapuna - North Shore Hospital
NCT06742996
Haem
Phase 3
Recruiting
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma (
BGB-11417-302
)
BTK inhibitor
Bcl2 inhibitor
placebo
Mantle cell lymphoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6005 - West Perth - Perth Blood Institute
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - One Clinical Research
6168 - Cooloongup - Rockingham Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
NCT06697184
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies. (
BGB-11417-108
)
Bcl2 inhibitor
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
WA
6009 - Nedlands - Linear Clinical Research
6168 - Cooloongup - Rockingham Hospital
NCT06634589
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies (
BGB-16673-104
)
BTK PROTAC degrader
B-cell lymphoma
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06588478
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor
BTK inhibitor
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2200 - Bankstown - Bankstown-Lidcombe Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3844 - Traralgon - Latrobe Regional Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6005 - West Perth - Perth Blood Institute
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06564038
Haem
Phase 1 / Phase 2
Recruiting
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies (
Soundtrack-E
)
bispecific T-cell engager,CD19-targeting
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Mantle cell lymphoma
Non-Hodgkin's lymphoma
Small lymphocytic lymphoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06528301
Haem
Phase 1
Recruiting
A Phase 1, Multicenter, Open-label Study of UB-VV111 in Combination With Rapamycin in Relapsed/Refractory (R/R) CD19+ B-cell Malignancies (
UB-VV111-01
)
gene therapy,CAR-T-cell generating,CD19-targeting
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Lymphoma
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
NCT06526793
Haem
Phase 2
Recruiting
A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (
SOUNDTRACK-B
)
bispecific T-cell engager,CD19-targeting
Diffuse large B-cell lymphoma
Follicular lymphoma
Non-Hodgkin's lymphoma
NSW
2109 - North Ryde - Macquarie University Hospital
2217 - Kogarah - St George Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06508658
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (
EPCORE-DLBCL-4
)
anti-CD20 monoclonal antibody
antimetabolite
bispecific T-cell engager,CD20-targeting
immunomodulatory imide drug
platinum-based antineoplastic agent
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4350 - Toowoomba - Toowoomba Hospital
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT06504394
Haem
Phase 2
Recruiting
A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (
3475A-F65
)
anti-PD-1 monoclonal antibody
Classical Hodgkin Lymphoma
Diffuse large B-cell lymphoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06492304
Haem
Phase 1
Recruiting
A Phase 1/2 Dose Evaluation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed/Refractory Hematologic Malignancies (
CRSP-ONC-008
)
allogeneic CAR-T-cell therapy,CD70-targeting
Acute myeloid leukaemia
B-cell lymphoma
T-cell lymphoma
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06486051
Haem
Phase 2
Recruiting
A Phase 2 Trial to Evaluate the Efficacy and Safety of WZTL-002 in Patients With Relapsed or Refractory Large B-cell Lymphoma (
ENABLE-2
)
autologous CAR-T-cell therapy,CD19-targeting
Diffuse large B-cell lymphoma
Non-Hodgkin's lymphoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06428019
Haem
Phase 3
Recruiting
A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL (
M24-287
)
BTK inhibitor
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4812 - Townsville - Townsville University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT06414148
Paed
Phase 2
Recruiting
A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation With Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (
EpLCART
)
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
immunomodulatory imide drug
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06395103
Paed
Phase 1 / Phase 2
Recruiting
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (
9999-01A
)
anti-ROR1 antibody-drug conjugate
B-cell acute lymphoblastic leukaemia/lymphoma
Burkitt lymphoma
Diffuse large B-cell lymphoma
Ewing sarcoma
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT06356129
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (
GOLSEEK-1
)
CELMoD agent
placebo
Diffuse large B-cell lymphoma
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
QLD
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT06287398
Haem
Phase 2
Recruiting
A Trial to Assess the Safety and Efficacy of Epcoritamab-containing Combination Salvage Therapy Followed by Autologous Stem Cell Transplantation and Epcoritamab Consolidation in Patients With Relapsed Large B-cell Lymphoma (
NHL38
)
bispecific T-cell engager,CD20-targeting
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Lymphoma
VIC
3121 - Melbourne - Australasian Leukemia and Lymphoma Group
NCT06136559
Haem
Phase 3
Recruiting
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (
1026-011
)
BTK inhibitor
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (COMPLETED)
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NCT06079164
Haem
Phase 1
Recruiting
A Phase 1 Open-label, Single Arm, Multicenter Study Evaluating the Safety and Efficacy of KITE-197 in Subjects With Relapsed or Refractory Large B-cell Lymphoma (
KT-US-656-0601
)
autologous CAR-T-cell therapy,CD19-targeting
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT06047080
Haem
Phase 3
Recruiting
A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (
GO44145
)
alkylating agent
anthracycline
anti-CD20 monoclonal antibody
anti-CD79b antibody-drug conjugate
bispecific T-cell engager,CD20-targeting
glucocorticoid
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06022029
Haem
Phase 1
Recruiting
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas (
ON-5001
)
STING agonist
anti-PD-1 monoclonal antibody
Bladder cancer
Cancer
Carcinoma
Cervical cancer
Diffuse large B-cell lymphoma
Follicular lymphoma
Head and neck squamous cell carcinoma
Lymphoma
Mantle cell lymphoma
Skin cancer
Triple-negative breast cancer
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
QLD
4215 - Southport - Tasman Oncology
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05947851
Haem
Phase 3
Recruiting
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010) (
1026-010
)
BTK inhibitor
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3021 - St Albans - Western Health - Sunshine Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05896163
Haem
Phase 1 / Phase 2
Recruiting
A PHASE 1b/2, OPEN-LABEL STUDY OF PF-07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED, SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION (
MAPtivate-6
)
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
Diffuse large B-cell lymphoma
VIC
3002 - East Melbourne - Epworth Freemasons
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05828589
Haem
Phase 1
Recruiting
A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies (
BGB-21447-101
)
Bcl2 inhibitor
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma,Richter's transformation
Follicular lymphoma
Marginal zone lymphoma
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3168 - Clayton - Monash Medical Centre
QLD
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05643742
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies (
CRSP-ONC-006
)
allogeneic CAR-T-cell therapy,CD19-targeting
B-cell lymphoma
B-cell malignancy
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05618028
Haem
Phase 1
Recruiting
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies (
M23-324
)
MALT1 inhibitor
B-cell malignancy
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Non-Hodgkin's lymphoma
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
NCT05605899
Haem
Phase 3
Recruiting
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (
ZUMA-23
)
autologous CAR-T-cell therapy,CD19-targeting
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT05512390
Haem
Phase 1
Recruiting
A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies (
M22-716
)
anti-CD19 antibody-drug conjugate,glucocorticoid receptor modulator
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6009 - Nedlands - One Clinical Research
NCT05365659
Haem
Phase 1
Recruiting
A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas (NHL) (
IKS03-01
)
anti-CD19 antibody-drug conjugate
B-cell lymphoma
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Non-Hodgkin's lymphoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT05139017
Haem
Phase 2 / Phase 3
Recruiting
A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003) (
2140-003
)
anti-ROR1 antibody-drug conjugate
Diffuse large B-cell lymphoma
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05091424
Haem
Phase 1
Recruiting
A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (
BO43243
)
Bcl2 inhibitor
bispecific T-cell engager,CD20-targeting
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3168 - Clayton - Monash Medical Centre
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (COMPLETED)
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05006716
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies (
CaDAnCe-101
)
BTK PROTAC degrader
B-cell malignancy
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
Waldenström Macroglobulinemia
NSW
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6005 - West Perth - Perth Blood Institute
6009 - Nedlands - Linear Clinical Research
NCT04989803
Haem
Phase 1
Recruiting
A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma (
KT-US-499-0150
)
autologous CAR-T-cell therapy,CD19/CD20-targeting
B-cell lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
NCT04923048
Haem
Phase 1 / Phase 2
Recruiting
A Phase Ⅰ/Ⅱ, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GB261 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (
GB261-001
)
bispecific T-cell engager,CD20-targeting
B-cell lymphoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3199 - Frankston - Peninsula Health Frankston Hospital (TERMINATED)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT04920617
Haem
Phase 2
Recruiting
A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (
VITALIZE
)
alkylating agent
anti-PD-1 monoclonal antibody
cell therapy,T-cell immunotherapy
Diffuse large B-cell lymphoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NCT04895436
Haem
Phase 2
Recruiting
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia (
ReVenG
)
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT04728893
Haem
Phase 2
Recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies (
1026-003
)
BTK inhibitor
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Small lymphocytic lymphoma
Waldenström Macroglobulinaemia
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (COMPLETED)
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04637763
Haem
Phase 1
Recruiting
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) (
CB10A
)
allogeneic CAR-T-cell therapy,CD19-targeting
B-cell lymphoma
Lymphoma
Non-Hodgkin's lymphoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3121 - Richmond - Epworth Freemasons Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT04623541
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (
EPCORE™-CLL-1
)
bispecific T-cell engager,CD20-targeting
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Small lymphocytic lymphoma
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
SA
5042 - Bedford Park - Flinders Medical Centre
NCT04594642
Haem
Phase 1
Recruiting
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma (
D7400C00006
)
bispecific T-cell engager,CD19-targeting
Diffuse large B-cell lymphoma
Follicular lymphoma
High-grade B-cell lymphoma
Non-Hodgkin's lymphoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT04442022
Haem
Phase 2
Recruiting
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL) (
2020-000605-84--XPORT-DLBCL-030
)
XPO1 inhibitor
anti-CD20 monoclonal antibody
antimetabolite
glucocorticoid
Diffuse large B-cell lymphoma
NCT04332822
Haem
Phase 3
Recruiting
R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (
POLAR-BEAR
)
anti-CD79b antibody-drug conjugate
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2487 - Cudgen - Tweed Valley Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3066 - Epping - Northern Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT03601442
Paed
Available
Managed Access Program (MAP) Cohort Treatment Plan
CCTL019B2003I
to Provide Access for Patients With Out of Specification Leukapheresis Product and/or Out of Specification Manufactured Tisagenlecleucel (CTL019; Kymriah®)
autologous CAR-T-cell therapy,CD19-targeting
Acute lymphoblastic leukaemia
Diffuse large B-cell lymphoma
WA
6150 - Murdoch - Fiona Stanley Hospital (AVAILABLE)
NCT02966756
Haem
Phase 2
Recruiting
A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
M14-728
)
Bcl2 inhibitor
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
VIC
3168 - Clayton - Monash Medical Centre
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
ACTRN12625000673448
Haem
Phase 2
Not yet recruiting
Detection of Ultra-High Risk Large B-Cell Lymphoma for Early Delivery of Axicabtagene Ciloleucel: A therapeutic arm of the ALLG NHL34 CLARIFY study (
ALLG-NHL34-DA
)
autologous CAR-T-cell therapy,CD19-targeting
Diffuse large B-cell lymphoma
ACTRN12624001142527
Haem
Phase 4
Not yet recruiting
Safety analysis of 90-minute Obinutuzumab infusion in Chronic Lymphocytic Leukaemia (CLL) and Follicular Lymphoma (FL) patients (
nil
)
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Follicular lymphoma
QLD
4870 - Cairns - Cairns Base Hospital
ACTRN12623000620628
Haem
Phase 2
Recruiting
NHL38 Epco-Sandwich: A phase II multicentre, single arm, open-label trial of epcoritamab-containing combination salvage therapy followed by autologous stem cell transplantation and epcoritamab consolidation in patients with relapsed large B-cell lymphoma.
bispecific T-cell engager,CD20-targeting
Diffuse large B-cell lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12621001529831
Haem
Phase 2
Recruiting
NHL35 -An Australasian Leukaemia and Lymphoma Group open label phase II study of the effect of of R-CHOP in combination with pembrolizumab in patients with newly diagnosed primary mediastinal B Cell Lymphoma (PMBL). (
PACIFIC
)
anti-PD-1 monoclonal antibody
B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12621001361897
Haem
Phase 2
Not yet recruiting
A single arm, open-label study of efficacy and safety of the Exportin 1 inhibitor selinexor in relapsed/refractory CNS Lymphoma and in relapsed/refractory CNS Myeloma (
EXCLAIM
)
XPO1 inhibitor
Diffuse large B-cell lymphoma
Multiple myeloma
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
ACTRN12619001656123
Haem
Phase 1
Not yet recruiting
Clarifying the role of early application of CAR T cells in Primary refractory and early relapsed diffuse large B cell lymphoma patients. (
CLARIFY-NHL34
)
Carboplatin
Cyclophosphamide
Doxorubicin
Etoposide
Fludarabine
Ifosfamide
Mesna
Prednisolone
Rituximab
Vincristine
alkylating agent
anthracycline
anti-CD20 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,CD20-targeting
cytotoxic chemotherapy
glucocorticoid
immuno-oncology therapy,CD20-targeting
platinum-based antineoplastic agent
sodium mercaptoethanesulfonate
topoisomerase inhibitor
vinca alkaloid
Diffuse large B-cell lymphoma
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (46)
Not yet recruiting (4)
Recruitment Country and State
VIC (39)
NSW (31)
WA (25)
QLD (23)
NZ (14)
SA (12)
TAS (5)
ACT (3)
NT (1)
Phase
Phase 1 (13)
Phase 1 / Phase 2 (9)
Phase 2 (15)
Phase 2 / Phase 3 (1)
Phase 3 (11)
Phase 4 (1)
Trial Type
Haem (48)
Paed (3)
Cancer Therapy Class
CD20
49%
Bcl2
25%
CD19
25%
BTK
24%
cereblon
8%
PD-1
8%
PD-1/PD-L1
8%
ROR1
4%
CD79b
4%
IL-6
4%
XPO1
4%
PI3K delta
2%
mTOR
2%
mTORC1
2%
mTORC2
2%
CD70
2%
STING
2%
MALT1
2%
Facility
3004 - Melbourne, Southbank - Alfred Health (13)
3000 - Melbourne - Peter MacCallum Cancer Centre (10)
3168 - Clayton - Monash Medical Centre (9)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (9)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (9)
3065 - Fitzroy - St Vincent's Hospital Melbourne (8)
NZ.0622 - Takapuna - North Shore Hospital (8)
2139 - Concord - Concord Repatriation General Hospital (8)
2050 - Camperdown - Chris O'Brien Lifehouse (7)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (7)
4102 - Woolloongabba - Princess Alexandra Hospital (6)
3128 - Box Hill - Box Hill Hospital - Eastern Health (6)
6009 - Nedlands - Linear Clinical Research (6)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (6)
2217 - Kogarah - St George Hospital (5)
6005 - West Perth - Perth Blood Institute (5)
5042 - Bedford Park - Flinders Medical Centre (5)
7000 - Hobart - Royal Hobart Hospital (5)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (5)
6000 - Perth - Royal Perth Hospital (5)
4575 - Birtinya - Sunshine Coast University Hospital (4)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (4)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (4)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (4)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (4)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
6168 - Cooloongup - Rockingham Hospital (3)
6009 - Nedlands - One Clinical Research (3)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (3)
2605 - Garran - The Canberra Hospital (3)
3002 - East Melbourne - Epworth Freemasons (3)
6150 - Murdoch - Fiona Stanley Hospital (3)
3021 - St Albans - Western Health - Sunshine Hospital (3)
3199 - Frankston - Peninsula Health Frankston Hospital (3)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (3)
3066 - Epping - Northern Hospital (3)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
2109 - North Ryde - Macquarie University Hospital (2)
4350 - Toowoomba - Toowoomba Hospital (2)
NZ.9016 - Dunedin - Dunedin Hospital (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (2)
2500 - Wollongong - Wollongong Hospital (2)
4215 - Southport - Gold Coast University Hospital (2)
NZ.3210 - Hamilton - Waikato Hospital (2)
2031 - Randwick - Prince of Wales Hospital (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
3121 - Richmond - Epworth Freemasons Hospital (2)
2170 - Liverpool - Liverpool Hospital (2)
2480 - Lismore - Lismore Base Hospital (1)
2500 - Wollongong - Wollongong Private Hospital (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
4812 - Townsville - Townsville University Hospital (1)
2031 - Randwick - Sydney Children's Hospital (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
3121 - Melbourne - Australasian Leukemia and Lymphoma Group (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
4215 - Southport - Tasman Oncology (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2487 - Cudgen - Tweed Valley Hospital (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
4870 - Cairns - Cairns Base Hospital (1)
Cancer Type
B-cell lymphoma
B-cell malignancy
Cancer
Haematological malignancy
Lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Leukaemia
Lymphoid leukaemia
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Acute lymphoblastic leukaemia
Solid tumour
Waldenström Macroglobulinaemia
Classical Hodgkin Lymphoma
Hodgkin's lymphoma
Acute myeloid leukaemia
Myeloid leukaemia
T-cell lymphoma
B-cell acute lymphoblastic leukaemia/lymphoma
Bone cancer
Burkitt lymphoma
Ewing family of tumours
Ewing sarcoma
Neuroblastic tumour
Neuroblastoma
Neurological cancer
Peripheral nervous system tumour
Primitive neuroectodermal tumour
Sarcoma
Bladder cancer
Breast adenocarcinoma
Breast cancer
Carcinoma
Cervical cancer
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Melanoma
Skin cancer
Triple-negative breast cancer
Urogenital cancer
Uveal melanoma
Viral-related cancer
Diffuse large B-cell lymphoma,Richter's transformation
Multiple myeloma
Plasma cell disorder
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy